Show simple item record

dc.contributor.authorMashayekhi, SO
dc.contributor.authorHain, RDW
dc.contributor.authorBuss, DC
dc.contributor.authorRoutledge, PA
dc.date.accessioned2018-08-26T09:31:11Z
dc.date.available2018-08-26T09:31:11Z
dc.date.issued2007
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/56935
dc.description.abstractThe aim of this study was to contrast protein binding of morphine and morphine-6 glucuronide in cord blood and children with adults and examine impact of chemotherapy and other factors. Morphine binding was measured in spiked samples from 18 adults and 18 neonates (cord blood), and compared with six children with cancer receiving morphine. The influence of the following was examined: Human serum albumin (HSA), alpha-1 acid glycoprotein (AAG), non-esterified fatty acids (NEFA); palmitic acid and oleic acid, pH, vincristine, methotrexate, 6-mercaptopurine and M6G. binding correlated with concentrations of albumin and alpha1 acid glycoprotein. In vitro, binding was not altered by vincristine, 6-mercaptopurine, methotrexate or M6G. Compared with HSA alone, AAG increased binding, palmitic acid reduced it and oleic acid had no effect. Binding was unaffected by pH in samples from patients. Morphine binding was influenced by concentrations of albumin, AAG and morphine itself, but not by age. Copyright ط¢آ© by The Haworth Press, Inc. All rights reserved.
dc.language.isoEnglish
dc.relation.ispartofJournal of Pain and Palliative Care Pharmacotherapy
dc.subjectalbumin
dc.subjectfatty acid
dc.subjecthuman serum albumin
dc.subjectmercaptopurine
dc.subjectmethotrexate
dc.subjectmorphine
dc.subjectmorphine 6 glucuronide
dc.subjectoleic acid
dc.subjectorosomucoid
dc.subjectpalmitic acid
dc.subjectvincristine
dc.subjectadolescent
dc.subjectadult
dc.subjectage
dc.subjectarticle
dc.subjectcancer
dc.subjectcancer patient
dc.subjectchemotherapy
dc.subjectcontrolled study
dc.subjectcorrelation analysis
dc.subjectdrug mechanism
dc.subjectdrug protein binding
dc.subjectfemale
dc.subjecthigh performance liquid chromatography
dc.subjecthuman
dc.subjectin vitro study
dc.subjectmale
dc.subjectpalliative therapy
dc.subjectpH
dc.subjectpreschool child
dc.subjectschool child
dc.subjectsingle drug dose
dc.subjecttablet
dc.subjectumbilical cord blood
dc.subject6-Mercaptopurine
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAge Factors
dc.subjectAnalgesics, Opioid
dc.subjectAntineoplastic Agents
dc.subjectBlood Proteins
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectFatty Acids, Nonesterified
dc.subjectFemale
dc.subjectFetal Blood
dc.subjectHumans
dc.subjectHydrogen-Ion Concentration
dc.subjectInfant, Newborn
dc.subjectMale
dc.subjectMethotrexate
dc.subjectMiddle Aged
dc.subjectMorphine
dc.subjectMorphine Derivatives
dc.subjectNeoplasms
dc.subjectOrosomucoid
dc.subjectProtein Binding
dc.subjectSerum Albumin
dc.subjectVincristine
dc.titleMorphine in children with cancer: Impact of age, chemotherapy and other factors on protein binding
dc.typeArticle
dc.citation.volume21
dc.citation.issue4
dc.citation.spage5
dc.citation.epage12
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.1300/J354v21n04_03


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record